"You seem to be grasping at straws now, in order to try to find a negative in all these positives for MSB."
You might have been too jaundiced in your viewpoint to notice it, but as a reminder, here's my take on the latest development in relation to the heart trial:
"...it's strategically smart, so kudos to management for pre-empting whatever direction Teva might choose to take."
I suspect (at least I hope) than any remotely objective jury of our peers might consider "strategically smart" and "kudos to management" to be somewhat non-negative phrases; positive, even. No?
"How can getting products to market early be seen as a negative?"
Where did I say it was negative?
On the contrary, given it is a good thing, my contemplation - articulated quite clearly, I thought - was why getting "products to market early" wasn't the plan initially, as it is now.
As for "shouting (you) down when (you) quite reasonably speculated that the FDA would ease up on clinical trials for stem cell therapies", feel free to show where I did anything of the kind.
MSB Price at posting:
$4.30 Sentiment: None Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)